KURA ONCOLOGY, INC.

(KURA)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
18.50 USD   +0.93%
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Credit Suisse Lifts Kura Oncology's Price Target to $27 from $25, Notes Rich Catalyst Lineup Into H2; Keeps Outperform Rating

02/25/2022 | 11:24am EDT


© MT Newswires 2022
All news about KURA ONCOLOGY, INC.
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash 2022 321 M - -
P/E ratio 2022 -8,34x
Yield 2022 -
Capitalization 1 221 M 1 221 M -
EV / Sales 2022 -
EV / Sales 2023 48,4x
Nbr of Employees 117
Free-Float 94,4%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 18,33 $
Average target price 35,88 $
Spread / Average Target 95,7%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President, CEO & Chief Financial Officer
Mollie Leoni Senior Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Faheem Hasnain Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.30.93%1 221
GILEAD SCIENCES, INC.-14.87%77 529
VERTEX PHARMACEUTICALS28.32%72 069
REGENERON PHARMACEUTICALS, INC.-6.40%63 692
WUXI APPTEC CO., LTD.-13.31%45 031
BIONTECH SE-42.16%36 234